SML3004

NMDAR/TRPM4 interface inhibitor C8 dihydrochloride

≥98% (HPLC)

• Synonym(e): C8 dihydrochloride, Compound 8 dihydrochloride, N1-[(3-Bromophenyl)methyl]-N1-ethyl-1,2-ethanediamine dihydrochloride
• Empirische Formel (Hill-System): C₁₁H₁₇BrN₂·2HCl
• CAS-Nummer: 2243506-33-2
• Molekulargewicht: 330.09
• MDL-Nummer: MFCD31668685
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder or solid
• Lagerbedingungen: desiccated
• Farbe: white to beige
• Löslichkeit: H₂O: 2 mg/mL, clear
• Lagertemp.: −20°C
• SMILES String: NCCN(CC)CC1=CC=CC(Br)=C1.Cl.Cl

Beschreibung

Biochem./physiol. Wirkung

Compound 8 (C8) is a small molecule that directly targets TRPM4 TwinF domain and blocks its interaction with GluN2A/GluN2B (NR2A/NR2B) I4 domain. C8 prevents NMDAR/TRPM4 interaction-dependent excitotoxicity (death protection EC50 = 2.1 μM 24 h post 10-min exposure of primary murine hippocampal neurons to 20 μM NMDA) without affecting, and even enhancing, NMDAR-mediated essential functions. C8 protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell (RGC) loss in mice in vivo (40 mg/kg i.p. at -16h, -3h before, 0h, 3h, 24h after MCAO or 20 nmol NMDA/2.0 μL by intravitreal injection).

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable